Tennor Therapeutics (Suzhou) Ltd (hkse:06872) Share Price

Company Profile

Business description
Tennor Therapeutics (Suzhou) Ltd is a near-commercial stage biotechnology company. Along with its subsidiaries, the company is principally engaged in the research and development as well as commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Its two core products are: rifotenizole (TNP-2198), a NME drug candidate developed for the treatment of H. pylori infection; and rifaquinone (TNP-2092 injection, a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections.
Contact
218 Xinghu Street
Unit 701, Block B7, Suzhou Industrial Park
Suzhou Area of China (Jiangsu), BioBay
Pilot Free Trade Zone Suzhou
Jiangsu
CHN
T: +86 51286861990
http://www.tennortherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees

Recommended

Aussie stock exchange remains materially undervalued despite growing cost concerns.

Roy Van Keulen | 29 May 2026

Questions surround Australia’s largest data center developer and its growing pipeline.

Yingqi Tan, CFA | 29 May 2026

The e-commerce business continues its sales momentum despite challenging backdrop.

Johannes Faul, CFA | 28 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,965.00	77.80	0.88%
CAC 40	8,183.34	5.53	-0.07%
DAX 40	25,104.70	12.45	0.05%
Dow JONES (US)	51,032.46	363.49	0.72%
FTSE 100	10,409.28	16.68	-0.16%
HKSE	25,182.39	176.23	0.70%
NASDAQ	26,972.62	55.15	0.20%
Nikkei 225	66,329.50	1,636.38	2.53%
NZX 50 Index	13,244.55	38.44	0.29%
S&P 500	7,580.06	16.43	0.22%
S&P/ASX 200	8,731.70	73.10	0.84%
SSE Composite Index	4,068.57	30.07	-0.73%